GlaxoSmithKline (GSK) Announces Divestiture of non-Core Assets to Aspen

September 12, 2016 7:35 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

GlaxoSmithKline (NYSE: GSK) announces a series of agreements with Aspen aligned with GSK’s strategy of simplification through focusing on core therapeutic areas.

GSK will divest its anaesthesia portfolio to Aspen for £180 million plus milestones of up to £100 million. In addition to this divestment, GSK and Aspen have entered into parallel agreements to terminate their collaboration in Sub-Saharan Africa and for Aspen to exercise its option to acquire GSK’s remaining thrombosis business in certain retained markets.

The agreements announced today are subject to the relevant anti-trust and regulatory clearances.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Mergers and Acquisitions, Spinoffs

Related Entities

Definitive Agreement

Add Your Comment